Literature DB >> 3935472

Trypanosoma cruzi: protection in mice immunized with 8-methoxypsoralen-inactivated trypomastigotes.

N W Andrews, M J Alves, R I Schumacher, W Colli.   

Abstract

Trypomastigote forms from the Y strain of Trypanosoma cruzi were inactivated by treatment with 8-methoxypsoralen and ultraviolet radiation (365 nm). The parasite population maintained normal morphology, mobility, and mammalian cell invasion capacity, being incapable of intracellular differentiation and reproduction. A strong protection of inbred A/Snell mice against challenges with virulent T. cruzi forms was obtained through three inoculations of the inactivated trypomastigotes. All immunized mice survived, with negative parasitemias and absence of tissue lesions. Several antibody-mediated reactions were performed with sera from the protected mice at distinct stages of the experiment. The levels of agglutinating, lytic (complement-mediated), and protein A binding antibodies increased progressively with each immunizing booster. The trypomastigote surface proteins recognized by antibodies present in these sera were identified after immunoprecipitation and two-dimensional polyacrylamide gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935472     DOI: 10.1016/0014-4894(85)90029-3

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Trypanosoma cruzi: properties of a clone isolated from CL strain.

Authors:  M T Lima; A M Jansen; E Rondinelli; C R Gattass
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

3.  Characterization of the inositol phosphorylceramide synthase activity from Trypanosoma cruzi.

Authors:  Juliana M Figueiredo; Wagner B Dias; Lucia Mendonça-Previato; José O Previato; Norton Heise
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

4.  Growth inhibition of Trypanosoma cruzi in cultured murine myocardial cells mediated by a specifically induced lymphokine.

Authors:  L Reyes; M Chinchilla
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

5.  Oligopeptidase B-dependent signaling mediates host cell invasion by Trypanosoma cruzi.

Authors:  E V Caler; S Vaena de Avalos; P A Haynes; N W Andrews; B A Burleigh
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

6.  Immunization with Trypanosoma cruzi epimastigote antigens incorporated into iscoms protects against lethal challenge in mice.

Authors:  F G Araujo; B Morein
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

7.  Resistance to acute Trypanosoma cruzi infection resulting from immunization of mice with a 90-kilodalton antigen from metacyclic trypomastigotes.

Authors:  J González; M F Araguth; N Yoshida
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

8.  Development of resistance to Trypanosoma cruzi in mice depends on a viable population of L3T4+ (CD4+) T lymphocytes.

Authors:  F G Araujo
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

9.  The toxic effects of piperine against Trypanosoma cruzi: ultrastructural alterations and reversible blockage of cytokinesis in epimastigote forms.

Authors:  Leonardo Freire-de-Lima; Tatiana Santana Ribeiro; Gustavo Miranda Rocha; Bruno Alves Brandão; Alexandre Romeiro; Lucia Mendonça-Previato; José Osvaldo Previato; Marco Edilson Freire de Lima; Técia Maria Ulisses de Carvalho; Norton Heise
Journal:  Parasitol Res       Date:  2008-01-29       Impact factor: 2.289

10.  Evidence for the participation of the Ssp-3 antigen in the invasion of nonphagocytic mammalian cells by Trypanosoma cruzi.

Authors:  S Schenkman; T Kurosaki; J V Ravetch; V Nussenzweig
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.